-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor On January 24, 2022, Lyell Immunopharma announced that the U.
S.
FDA has approved the IND application for a Phase 1 clinical trial of the investigational T cell receptor (TCR) therapy LYL132 for the treatment of New York esophageal squamous cell carcinoma patients with solid tumors with neoplasm 1 (NY-ESO-1) antigen
.
NY-ESO-1 is a cancer testis antigen (CTA) expressed in a variety of solid tumors but rarely in normal tissues
.
The therapy is currently being co-developed by Lyell and GlaxoSmithKline (GSK)
.
According to the press release, the Phase 1 clinical trial will evaluate the efficacy and safety of LYL132 in patients with advanced synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCLS) expressing NY-ESO-1, and Lyell is responsible for the manufacture of the therapy.
, GlaxoSmithKline will be responsible for conducting clinical trials
.
NY-ESO-1 is a member of the CTA family of tumor-associated antigens and is a clinically validated therapeutic target that is highly expressed in various solid tumor types, including non-small cell lung cancer, bladder cancer, SS, and MRCLS
.
SS is a rare malignant tumor of soft tissue, accounting for approximately 5-10% of all soft tissue sarcomas
.
Patients often develop cancer metastasis, especially lung metastasis, resulting in a 10-year survival rate of less than 50%
.
One of the most common types of liposarcoma, accounting for about 30 percent of all cases, MRCLS is a rare soft connective tissue tumor that grows in the body's fat-storing cells, usually in the arms and legs
.
When cancer metastasis occurs, the 5-year survival rate of patients is about 40%
.
LYL132 incorporates Lyell's ex vivo epigenetic reprogramming technology, Epi-R
.
This technology is designed to overcome a major obstacle to adoptive T cell therapy by generating T cell populations with durable stem cell properties to achieve clinically meaningful and long-term clinical responses
.
Persistent stem cell characteristics are the ability of T cells to persist, self-renew and proliferate while maintaining anticancer effects
.
▲Dr.
Rick Klausner shared his insights on cell therapy development at the 2020 WuXi AppTec Global Forum Related reading: Farewell to the "Stone Age" of Cell Therapy | Dr.
Rick Klausner, Chairman of the Lyell Board of Directors of WuXi AppTec Global Forum, said: The clinical evaluation of the potential benefits of reprogrammed T cells with durable stem cell properties is an important and exciting milestone for Lyell and cancer drug development
.
We believe that T cells lacking durable stem cell properties are an ACT therapy A major barrier to solid tumors, and expect our Epi-R technology platform to provide patients with a path to better clinical outcomes
.
"Reference: [1] Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK.
Retrieved January 24, 2022, from https:// news-release/2022/01/24/2371644/0/en/Lyell-Immunopharma-Announces-FDA-Clearance-of-IND-for-LYL132-aT-Cell-Receptor-Therapy-for-Solid-Tumors-Being- Developed-in-Collaboration-with-GSK.
htmlDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views in this article do not represent WuXi AppTec's position, nor do they represent WuXi PharmaTech Kant supports or opposes the views in the article
.
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
S.
FDA has approved the IND application for a Phase 1 clinical trial of the investigational T cell receptor (TCR) therapy LYL132 for the treatment of New York esophageal squamous cell carcinoma patients with solid tumors with neoplasm 1 (NY-ESO-1) antigen
.
NY-ESO-1 is a cancer testis antigen (CTA) expressed in a variety of solid tumors but rarely in normal tissues
.
The therapy is currently being co-developed by Lyell and GlaxoSmithKline (GSK)
.
According to the press release, the Phase 1 clinical trial will evaluate the efficacy and safety of LYL132 in patients with advanced synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCLS) expressing NY-ESO-1, and Lyell is responsible for the manufacture of the therapy.
, GlaxoSmithKline will be responsible for conducting clinical trials
.
NY-ESO-1 is a member of the CTA family of tumor-associated antigens and is a clinically validated therapeutic target that is highly expressed in various solid tumor types, including non-small cell lung cancer, bladder cancer, SS, and MRCLS
.
SS is a rare malignant tumor of soft tissue, accounting for approximately 5-10% of all soft tissue sarcomas
.
Patients often develop cancer metastasis, especially lung metastasis, resulting in a 10-year survival rate of less than 50%
.
One of the most common types of liposarcoma, accounting for about 30 percent of all cases, MRCLS is a rare soft connective tissue tumor that grows in the body's fat-storing cells, usually in the arms and legs
.
When cancer metastasis occurs, the 5-year survival rate of patients is about 40%
.
LYL132 incorporates Lyell's ex vivo epigenetic reprogramming technology, Epi-R
.
This technology is designed to overcome a major obstacle to adoptive T cell therapy by generating T cell populations with durable stem cell properties to achieve clinically meaningful and long-term clinical responses
.
Persistent stem cell characteristics are the ability of T cells to persist, self-renew and proliferate while maintaining anticancer effects
.
▲Dr.
Rick Klausner shared his insights on cell therapy development at the 2020 WuXi AppTec Global Forum Related reading: Farewell to the "Stone Age" of Cell Therapy | Dr.
Rick Klausner, Chairman of the Lyell Board of Directors of WuXi AppTec Global Forum, said: The clinical evaluation of the potential benefits of reprogrammed T cells with durable stem cell properties is an important and exciting milestone for Lyell and cancer drug development
.
We believe that T cells lacking durable stem cell properties are an ACT therapy A major barrier to solid tumors, and expect our Epi-R technology platform to provide patients with a path to better clinical outcomes
.
"Reference: [1] Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK.
Retrieved January 24, 2022, from https:// news-release/2022/01/24/2371644/0/en/Lyell-Immunopharma-Announces-FDA-Clearance-of-IND-for-LYL132-aT-Cell-Receptor-Therapy-for-Solid-Tumors-Being- Developed-in-Collaboration-with-GSK.
htmlDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views in this article do not represent WuXi AppTec's position, nor do they represent WuXi PharmaTech Kant supports or opposes the views in the article
.
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
